Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Cacumen platycladi extract significantly promoted hair growth and reduced dihydrotestosterone levels by inhibiting 5α-reductase activity in an androgen-sensitive mouse model.

This study found that three months of oral finasteride treatment significantly decreased dihydrotestosterone levels and hair growth in hirsute women without negatively affecting gonadotropin secretion.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.

In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.

This study concluded that administering dutasteride for more than 8 weeks in rats could lead to irreversible erectile dysfunction, even after stopping the medication.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.

This study found that progesterone derivatives with chlorine or bromine substituents were effective in inhibiting 5α-reductase activity in human prostate and exhibited antiandrogenic effects in hamster flank organs.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This study found that inhibiting 5α-reductase in molluscs provokes a specific shell morphology, suggesting gastropods might have unique 5α-reductase substrates absent in vertebrates.

This review suggests that while finasteride for male pattern hair loss was previously considered safe, there is now evidence associating 5-α reductase inhibitors with significant sexual and reproductive side effects.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.

This study found that in men with sexual dysfunction, use of 5ARI may reduce sexual drive and spontaneous erections without worsening pre-existing erectile or ejaculatory issues.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This study reported that newly synthesized progesterone derivatives significantly reduced prostate weight in testosterone-treated hamsters, with 5alpha-reductase inhibitory activity dependent on the size of the substituent at C-17.

This study proposes that the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia may contribute to poorer COVID-19 prognosis in males.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.